计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| S302239-1g |
1g |
现货 ![]() |
| |
| S302239-5g |
5g |
现货 ![]() |
| |
| S302239-25g |
25g |
现货 ![]() |
|
| 别名 | 东莨菪碱氢溴酸盐 | 氢溴酸东莨菪碱 | 天仙子碱 氢溴酸盐 | 莨菪胺 | (-)-东莨菪碱 氢溴酸盐 |
|---|---|
| 英文别名 | (-)-Hyoscine hydrobromide | CAS-114-49-8 | HY-N0296A | HYOSCINE HYDROBROMIDE [WHO-DD] | NSC8847 | R3K67DRL3J | WTGQALLALWYDJH-WYHSTMEOSA-N | (?,S)-?-(Hydroxymethyl)benzeneacetic acid (1?,2?,4?,5?,7?)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl ester |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | (-)-Scopolamine hydrobromide |
| 生化机理 | 竞争性非选择性毒蕈碱拮抗剂。测量体内认知障碍的标准工具。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 拮抗剂 |
| 作用机制 | M 1 受体拮抗剂;M 2 受体拮抗剂;M 3 受体拮抗剂;M 4 受体拮抗剂;M 5 受体拮抗剂 |
| 备注 | 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
| 产品介绍 |
Scopolamine hydrobromide 是高亲和力的 (nM 级别) 毒蕈碱 (muscarinic) 拮抗剂。Scopolamine 可逆抑制 5-HT3 受体反应,IC50 为 2.09 μM。 Scopolamine hydrobromide is a high affinity (nM) muscarinic antagonist. 5-HT3 receptor-responses are reversibly inhibited by Scopolamine with an IC50 of 2.09 μM. |
| 纯度 | ≥98% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | [(1R,2R,4S,5S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate;hydrobromide |
| INCHI | 1S/C17H21NO4.BrH/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10;/h2-6,11-16,19H,7-9H2,1H3;1H/t11?,12-,13-,14+,15-,16+;/m1./s1 |
| InChi Key | WTGQALLALWYDJH-WYHSTMEOSA-N |
| Smiles | CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4.Br |
| Isomeric SMILES | CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4.Br |
| PubChem CID | 6603108 |
| 分子量 | 384.26 |
| 溶解性 | Soluble in water (77 mg/mL), DMSO (77 mg/mL), Insoluble in ethanol. |
|---|---|
| 敏感性 | 对湿度敏感 |
| 熔点 | 195-199 °C (dry matter)(lit.) |
| 分子量 | 384.300 g/mol |
| XLogP3 | |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 5 |
| 可旋转键计数Rotatable Bond Count | 5 |
| 精确质量Exact Mass | 383.073 Da |
| 单同位素质量Monoisotopic Mass | 383.073 Da |
| 拓扑极表面积Topological Polar Surface Area | 62.300 Ų |
| 重原子数Heavy Atom Count | 23 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 418.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 5 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 2 |
| 象形图 | GHS06 |
|---|---|
| 信号词 | 危险 |
| 危险声明 |
H300: 吞咽致命 H302: 吞食有害 H310: 与皮肤接触致命 H330: 吸入致命 H361: 怀疑破坏生育力或未出生的孩子 |
| 预防措施声明 |
P260: 不要吸入灰尘/烟雾/气体/雾/蒸汽/喷雾。 P262: 不要进入眼睛、皮肤或衣服。 P264: 处理后要彻底洗手。 P270: 使用本产品时,请勿进食、饮水或吸烟。 P271: 仅在室外或通风良好的地方使用。 P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 P284: 如果通风不良,请佩戴呼吸防护装置。 P320: 迫切需要特殊治疗(请参阅此标签上的...)。 P321: 特殊处理(请参阅此标签上的...)。 P330: 漱口 P302+P352: 如皮肤沾染:用水充分清洗。 P304+P340: 如误吸入:将人转移到空气新鲜处,保持呼吸舒适体位。 P361+P364: 立即脱掉所有沾染的衣服,清洗后方可重新使用。 P405: 密闭存放 P403+P233: 存放在通风良好的地方。保持容器密闭。 P501: 将内容物/容器处理到。。。 P203: 使用前,获取、阅读并遵守所有安全说明。 P301+P316: 如果吞咽:立即寻求紧急医疗救助。 P301+P317: 如果被吞咽:请寻求医疗帮助。 P318: 如果暴露或担心,请就医。 P316: 立即寻求紧急医疗救助。 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | S302239 | |
| 分析证书 | S302239 | |
| 分析证书 | S302239 | |
| 分析证书 | S302239 | |
| 分析证书 | S302239 | |
| 分析证书 | S302239 | |
| 分析证书 | S302239 | |
| 分析证书 | S302239 | |
| 分析证书 | S302239 | |
| 分析证书 | S302239 | |
| 分析证书 | S302239 | |
| 分析证书 | S302239 | |
| 分析证书 | S302239 | |
| 分析证书 | S302239 | |
| 分析证书 | S302239 | |
| 分析证书 | S302239 | |
| 分析证书 | S302239 | |
| 分析证书 | S302239 | |
| 分析证书 | S302239 | |
| 分析证书 | S302239 |
¥119.90
| 1. Guoxing Wang, Jiyu Du, Jie Ma, Peipei Liu, Siqi Xing, Jucheng Xia, Shuanghong Dong, Zeng Li. (2023) Discovery of Novel Tryptanthrin Derivatives with Benzenesulfonamide Substituents as Multi-Target-Directed Ligands for the Treatment of Alzheimer’s Disease. Pharmaceuticals, 16 (10): (1468). [PMID:37895939] [10.3390/ph16101468] |
| 2. Xi Zhu, Yangjing Lv, Miaoliang Fan, Jianan Guo, Yujia Zhang, Bianbian Gao, Changjun Zhang, Yuanyuan Xie. (2023) Exploration of the novel phthalimide-hydroxypyridinone derivatives as multifunctional drug candidates against Alzheimer’s disease. BIOORGANIC CHEMISTRY, 141 (106817). [PMID:37690318] [10.1016/j.bioorg.2023.106817] |
| 3. Changjun Zhang, Yujia Zhang, Yangjing Lv, Jianan Guo, Bianbian Gao, Yi Lu, Anjie Zang, Xi Zhu, Tao Zhou, Yuanyuan Xie. (2023) Chromone-based monoamine oxidase B inhibitor with potential iron-chelating activity for the treatment of Alzheimer’s disease. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, [PMID:36519319] [10.1080/14756366.2022.2134358] |
| 4. Chuansheng Yao, Xiaoying Jiang, Rui Zhao, Zhichao Zhong, Jiamin Ge, Junlong Zhu, Xiang-Yang Ye, Yuanyuan Xie, Zhen Liu, Tian Xie, Renren Bai. (2022) HDAC1/MAO-B dual inhibitors against Alzheimer’s disease: Design, synthesis and biological evaluation of N-propargylamine-hydroxamic acid/o-aminobenzamide hybrids. BIOORGANIC CHEMISTRY, 122 (105724). [PMID:35305483] [10.1016/j.bioorg.2022.105724] |
| 5. Min Wang, Longji Fang, Tongtong Liu, Xuejie Chen, Yan Zheng, Yilong Zhang, Shiming Chen, Zeng Li. (2021) Discovery of 7-O-1, 2, 3-triazole hesperetin derivatives as multi-target-directed ligands against Alzheimer's disease. CHEMICO-BIOLOGICAL INTERACTIONS, 342 (109489). [PMID:33905740] [10.1016/j.cbi.2021.109489] |
| 6. Yilei Song, Xiangyu Wang, Xingrong Wang, Jianze Wang, Qiulian Hao, Jifu Hao, Xueqin Hou. (2021) Osthole-Loaded Nanoemulsion Enhances Brain Target in the Treatment of Alzheimer’s Disease via Intranasal Administration. Oxidative Medicine and Cellular Longevity, 2021 (8844455). [PMID:33564364] [10.1155/2021/8844455] |
| 7. Huimin Wu, Longfei Lin, Xueying Du, Lingling Zhang, Xingbin Yin, Xiaoxv Dong, Xiaofeng Hao, Like Xie, Changhai Qu, Jian Ni. (2020) Study on the potential effective ingredients of Xiaosheng prescription for dry eye disease. BIOMEDICINE & PHARMACOTHERAPY, 127 (110051). [PMID:32428832] [10.1016/j.biopha.2020.110051] |
| 8. Xiaomeng Xu, Rong Liang, Dongmei Li, Chengyao Jiang, Songyi Lin. (2020) Evaluation of sea cucumber peptides-assisted memory activity and acetylation modification in hippocampus of test mice based on scopolamine-induced experimental animal model of memory disorder. Journal of Functional Foods, 68 (103909). [10.1016/j.jff.2020.103909] |
| 9. Huihong Zeng, Huan Li, Mengzhen Yue, Ying Fan, Jiaoqi Cheng, Xincheng Wu, Rui Xu, Wuping Yang, Manjun Li, Jiahui Tang, Hongping Chen, Bohai Kuang, Guangqin Fan, Qingxian Zhu, Lijian Shao. (2020) Isoprenaline protects intestinal stem cells from chemotherapy-induced damage. BRITISH JOURNAL OF PHARMACOLOGY, 177 (3): (687-700). [PMID:31648381] [10.1111/bph.14883] |
| 10. Yu-Min Xu, Xin-Chen Wang, Ting-Ting Xu, Hong-Ying Li, Shang-Yan Hei, Na-Chuan Luo, Hong Wang, Wei Zhao, Shu-Huan Fang, Yun-Bo Chen, Li Guan, Yong-Qi Fang, Shi-Jie Zhang, Qi Wang, Wei-Xiong Liang. (2019) Kai Xin San ameliorates scopolamine-induced cognitive dysfunction. Neural Regeneration Research, 14 (5): ( 794–804). [PMID:30688265] [10.4103/1673-5374.249227] |
| 11. Jing Zhang, Jun Wang, Gui-Sheng Zhou, Ya-Jie Tan, Hui-Juan Tao, Jia-Qian Chen, Zong-Jin Pu, Jia-Yan Ma, Wen She, An Kang, Yue Zhu, Pei Liu, Zhen-Hua Zhu, Xu-Qin Shi, Yu-Ping Tang, Jin-Ao Duan. (2019) Studies of the Anti-amnesic Effects and Mechanisms of Single and Combined Use of Donepezil and Ginkgo Ketoester Tablet on Scopolamine-Induced Memory Impairment in Mice. Oxidative Medicine and Cellular Longevity, 2019 (8636835). [PMID:30911351] [10.1155/2019/8636835] |
| 12. Sun Kaiyue, Bai Yuting, Zhao Rong, Guo Zijiao, Su Xiang, Li Peiqi, Yang Pengyu. (2019) Neuroprotective effects of matrine on scopolamine-induced amnesia via inhibition of AChE/BuChE and oxidative stress. METABOLIC BRAIN DISEASE, 34 (1): (173-181). [PMID:30406376] [10.1007/s11011-018-0335-y] |
| 13. Yao Chen, Jie Zhu, Jun Mo, Hongyu Yang, Xueyang Jiang, Hongzhi Lin, Kai Gu, Yuqiong Pei, Liang Wu, Renxiang Tan, Jing Hou, Jingyi Chen, Yang Lv, Yaoyao Bian, Haopeng Sun. (2018) Synthesis and bioevaluation of new tacrine-cinnamic acid hybrids as cholinesterase inhibitors against Alzheimer’s disease. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, [PMID:29278947] [10.1080/14756366.2017.1412314] |
| 14. Liang Meng, Pinjia Meng, Bugang Tang, Qingqing Zhang, Yanji Wang. (2013) Molecularly imprinted photonic hydrogels for fast screening of atropine in biological samples with high sensitivity. FORENSIC SCIENCE INTERNATIONAL, 231 (6). [PMID:23890610] [10.1016/j.forsciint.2013.04.008] |
| 15. Chen Y, Sun J, Fang L, Liu M, Peng S, Liao H, Lehmann J, Zhang Y.. (2012) Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors.. J Med Chem, 55 (9): (4309-4321). [PMID:22512543] [10.1021/jm300106z] |
| 16. Yao H, Uras G, Zhang P, Xu S, Yin Y, Liu J, Qin S, Li X, Allen S, Bai R, Gong Q, Zhang H, Zhu Z, Xu J.. (2021) Discovery of Novel Tacrine-Pyrimidone Hybrids as Potent Dual AChE/GSK-3 Inhibitors for the Treatment of Alzheimer's Disease.. J Med Chem, 64 (11.0): (7483-7506). [PMID:34024109] [10.1021/acs.jmedchem.1c00160] |
| 17. Li Ming-Jie, Xu Jing-Yi, Zhang Hua-Yue, Guo Min, Lan Meng-Ning, Kong Jie, Liu Shi-Wei, Zheng Hua-Jun. (2024) A medicine and food homology formula prevents cognitive deficits by inhibiting neuroinflammation and oxidative stress via activating AEA–Trpv1–Nrf2 pathway. INFLAMMOPHARMACOLOGY, (1-15). [PMID:39305407] [10.1007/s10787-024-01570-4] |
| 18. Yuanfang Sun, Qi Xia, Lijing Du, Yu Gan, Xiaopeng Ren, Gang Liu, Yongkuan Wang, Shikai Yan, Shasha Li, Xiuyun Zhang, Xue Xiao, Huizi Jin. (2024) Neuroprotective effects of Anshen Bunao Syrup on cognitive dysfunction in Alzheimer's disease rat models. BIOMEDICINE & PHARMACOTHERAPY, 176 (116754). [PMID:38810401] [10.1016/j.biopha.2024.116754] |